Revvity (PKI) Stock Price, News & Analysis

Company Overview

Revvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $115.24 to $137.11
• 52-Week Range: N/A
• Volume: 1.63 million shs
• Average Volume: 851,117 shs
• Market Capitalization: $14.57 billion
• P/E Ratio: 15.01
• Dividend Yield: 0.24%
• Price Target: N/A
• Consensus Rating: N/A

PKI Stock Analysis - Frequently Asked Questions

How were Revvity's earnings last quarter?

Revvity, Inc. (NYSE:PKI) posted its quarterly earnings data on Thursday, May, 11th. The medical research company reported $1.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.07 by $0.06. The medical research company had revenue of $674.87 million for the quarter, compared to analysts' expectations of $686.30 million. Revvity had a trailing twelve-month return on equity of 11.17% and a net margin of 28.94%.

Does Revvity have any subsidiaries?

The following companies are subsidiaries of Revvity: BioLegend, Immunodiagnostic Systems, Nexcelom Bioscience, SIRION Biotech, Oxford Immunotec, Horizon Discovery, Cisbio.com, and more.

What other stocks do shareholders of Revvity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Revvity investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Visa (V), Home Depot (HD) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 5/11/2023
• Today: 6/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:PKI
• CIK: 31791
• Web: www.perkinelmer.com
• Phone: (781) 663-6900
• Fax: 781-663-5985
• Employees: 16,700
• Year Founded: 1937

Profitability

• EPS (Most Recent Fiscal Year): $7.68
• Trailing P/E Ratio: 15.01
• Forward P/E Ratio: N/A
• P/E Growth: 0.5
• Net Income: $569.18 million
• Net Margins: 28.94%
• Pretax Margin: 13.81%
• Return on Equity: 11.17%
• Return on Assets: 5.83%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 2.43
• Quick Ratio: 2.15

Sales & Book Value

• Annual Sales: $3.31 billion
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 9.88
• Book Value: $58.49 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 126,410,000
• Free Float: 125,755,000
• Market Cap: $14.57 billion
• Optionable: Optionable
• Beta: 1.10